Methods and compositions for assessing and treating emetogenic drug-related nausea
AssigneeLankenau Institute for Medical Research
InventorMargaretha Wallon
Life of this patent
Estimating the term…
Abstract
A method for assessing susceptibility to nausea of a patient comprises assessing the GSH recycling dependent antioxidant activity of the patient's blood cells prior to receiving an emetogenic agent, e.g., a cytostatic agent or a surgical anesthetic.
Claims27
A method for assessing susceptibility to nausea comprising assaying a biological sample containing red blood cells (RBC) for glutathione (GSH) recycling dependent antioxidant activity of the RBC as an indicator of oxidative stress, said sample obtained from a mammalian subject prior to administration of an emetogenic agent, wherein a high level of oxidative stress is predictive of increased susceptibility to nausea.
(canceled)
(canceled)
(canceled)
10-14. (canceled)
(canceled)
The method according to claim 26 comprising:
- (a) providing at least one reagent capable of interacting with red blood cells and generating an indicator of oxidative stress in a blood sample of a patient obtained prior to treatment with an emetogenic agent;
- (b) detecting in said sample from said patient the level of oxidative stress by providing a measurement of GSH recycling dependent antioxidant activity in the RBC wherein a high or increased level of oxidative stress is predictive of susceptibility to nausea;
- (c) classifying the sample of said patient from the outcome of the comparison in step (b) into one of at least two classifications of low or high oxidative stress levels to permit selection of a drug regimen, wherein the drug regimen comprises the administration of two or less than two antiemetic drugs, or no antiemetic drug or three or more antiemetic drugs, before, during or after administration of
- (i) a high to moderately emetogenic cytostatic chemotherapeutic agent, where the subject has cancer;
- (ii) a low emetogenic cytostatic chemotherapeutic, where the subject has cancer;
- or
- (iii) an emetogenic anesthesia agent, wherein the subject is undergoing a surgical procedure.
(canceled)
A method of selecting a population for individualized therapeutic regimen comprising classifying a patient for the likelihood of developing nausea into a low likelihood or high likelihood category prior to selecting or administering a drug regimen comprising a high or moderately emetogenic agent with an antiemetic drug regimen comprising one to three antiemetic drugs or with an antiemetic drug regiment comprising greater than three antiemetic drugs.
(canceled)
A system or kit for determining whether a subject has a high or low nausea response to an emetogenic agent, said system or kit comprising:
- (a) assay reagents for measuring oxidative stress in the RBC of a whole blood sample taken from the subject prior to treatment with the emetogenic agent;
- and
- (b) a nausea phenotype determination element for determining whether said subject has a is predisposed to nausea or resistant to nausea, the phenotype determination element comprising a reference profile for an oxidative level of RBC, wherein the phenotype determination element is obtained from a sample from one of more patients with a nausea predisposed phenotype or a nausea resistant phenotype, wherein a high level of oxidative stress is predictive of susceptibility to nausea.
(canceled)
(canceled)
Dependencies are inferred from the claim text.